Retatrutide's Trial Data Is Genuinely Remarkable — Here's the Actual Numbers
45% of patients on Retatrutide's top dose lost 30%+ of body weight in Lilly's own TRIUMPH-1 data. The real numbers, and the one caveat that still matters.
Retatrutide has generated an enormous amount of online discussion, much of it flattened into "better than Ozempic" claims that skip past the actual numbers. The real trial data is genuinely strong, and worth presenting on its own terms.
The Numbers, Directly
The data comes from TRIUMPH-1, a real Phase 3 trial involving 2,339 patients over 80 weeks.
- 28.3% average weight loss on the 12mg dose group
- 45.3% of patients on that dose lost 30% or more of total body weight — a result in the range typically associated with bariatric surgery, not a medication
- 2.0 percentage point reduction in HbA1c in a second trial (TRANSCEND-T2D-1) of 537 patients with type 2 diabetes, alongside 16.8% weight loss
- An early sleep apnea substudy nested inside TRIUMPH-1 reporting positive results, suggesting effects may extend beyond weight loss alone
The Caveat That Matters
Retatrutide is not FDA approved and is not available by prescription as of 2026. Eli Lilly has the primary efficacy dataset needed for a New Drug Application filing, expected before the end of the year, but a filing is not an approval.
The real data here is strong enough to stand on its own without the hype-driven framing it usually gets online. It just is not, yet, an approved, prescribable medication.